Skip to main content
Skip to content
Case File
d-30422House Oversight

Cannabis Investment Report – Overview of FDA‑Approved Cannabinoid Pharmaceuticals (Dec 2017)

Other

The passage is a routine industry summary of approved cannabinoid drugs and their regulatory status. It contains no specific allegations, names of officials, financial transactions, or controversial a Lists FDA‑approved cannabinoid medicines: Marinol, Syndros, Cesamet, Sativex. Notes schedule classifications under the U.S. Controlled Substances Act. Mentions GW Pharmaceuticals as manufacturer of S

Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #024690
Pages
1
Persons
0
Integrity
No Hash Available
Loading document viewer...

Ask AI About This Document

0Share
PostReddit
Review This Document

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.